Inmune Bio (INMB) Total Debt (2021 - 2024)
Inmune Bio (INMB) has disclosed Total Debt for 4 consecutive years, with $5.0 million as the latest value for Q3 2024.
- Quarterly Total Debt fell 59.65% to $5.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Sep 2024, down 59.65% year-over-year, with the annual reading at $9.9 million for FY2023, 32.5% down from the prior year.
- Total Debt hit $5.0 million in Q3 2024 for Inmune Bio, down from $10.0 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $15.0 million in Q1 2024 to a low of $5.0 million in Q3 2024.
- Historically, Total Debt has averaged $13.1 million across 4 years, with a median of $14.5 million in 2021.
- Biggest five-year swings in Total Debt: rose 1.72% in 2023 and later tumbled 59.65% in 2024.
- Year by year, Total Debt stood at $14.5 million in 2021, then grew by 1.65% to $14.7 million in 2022, then crashed by 32.5% to $9.9 million in 2023, then plummeted by 49.66% to $5.0 million in 2024.
- Business Quant data shows Total Debt for INMB at $5.0 million in Q3 2024, $10.0 million in Q2 2024, and $15.0 million in Q1 2024.